238 related articles for article (PubMed ID: 18927296)
41. WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells.
Jiang W; Crossman DK; Mitchell EH; Sohn P; Crowley MR; Serra R
PLoS One; 2013; 8(3):e58329. PubMed ID: 23484019
[TBL] [Abstract][Full Text] [Related]
42. Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells.
Dejmek J; Säfholm A; Kamp Nielsen C; Andersson T; Leandersson K
Mol Cell Biol; 2006 Aug; 26(16):6024-36. PubMed ID: 16880514
[TBL] [Abstract][Full Text] [Related]
43. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
44. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion.
Jenei V; Sherwood V; Howlin J; Linnskog R; Säfholm A; Axelsson L; Andersson T
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19473-8. PubMed ID: 19901340
[TBL] [Abstract][Full Text] [Related]
45. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis.
Lei R; Tang J; Zhuang X; Deng R; Li G; Yu J; Liang Y; Xiao J; Wang HY; Yang Q; Hu G
Oncogene; 2014 Mar; 33(10):1287-96. PubMed ID: 23474751
[TBL] [Abstract][Full Text] [Related]
46. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
47. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
48. Human embryonic stem cell-derived endothelial cells as cellular delivery vehicles for treatment of metastatic breast cancer.
Su W; Wang L; Zhou M; Liu Z; Hu S; Tong L; Liu Y; Fan Y; Kong D; Zheng Y; Han Z; Wu JC; Xiang R; Li Z
Cell Transplant; 2013; 22(11):2079-90. PubMed ID: 23067802
[TBL] [Abstract][Full Text] [Related]
49. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling.
Hou J; Wang Z; Xu H; Yang L; Yu X; Yang Z; Deng Y; Meng J; Feng Y; Guo X; Yang G
PLoS One; 2015; 10(4):e0122179. PubMed ID: 25830567
[TBL] [Abstract][Full Text] [Related]
50. Wnt-5a has tumor suppressor activity in thyroid carcinoma.
Kremenevskaja N; von Wasielewski R; Rao AS; Schöfl C; Andersson T; Brabant G
Oncogene; 2005 Mar; 24(13):2144-54. PubMed ID: 15735754
[TBL] [Abstract][Full Text] [Related]
51. Wnt-5a is a synaptogenic factor with neuroprotective properties against Aβ toxicity.
Varela-Nallar L; Parodi J; Farías GG; Inestrosa NC
Neurodegener Dis; 2012; 10(1-4):23-6. PubMed ID: 22261402
[TBL] [Abstract][Full Text] [Related]
52. Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer.
Wang WQ; Zhao D; Zhou YS; Hu XY; Sun ZN; Yu G; Wu WT; Chen S; Kuang JL; Xu GG; Han ZC; Wang BM; Yang JX; Feng XM
Acta Pharmacol Sin; 2015 Apr; 36(4):528-34. PubMed ID: 25832432
[TBL] [Abstract][Full Text] [Related]
53. Nephronectin is Decreased in Metastatic Breast Carcinoma and Related to Metastatic Organs.
Dilmac S; Erin N; Demir N; Tanriover G
Pathol Oncol Res; 2018 Jul; 24(3):679-688. PubMed ID: 28842827
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of Breast Cancer Metastasis by Pluronic Copolymers with Moderate Hydrophilic-Lipophilic Balance.
Sun H; Meng Q; Tang S; Su J; Yin Q; Chen L; Gu W; Yu H; Zhang Z; Wang S; Li Y
Mol Pharm; 2015 Sep; 12(9):3323-31. PubMed ID: 26220770
[TBL] [Abstract][Full Text] [Related]
55. WNT-5A: signaling and functions in health and disease.
Kumawat K; Gosens R
Cell Mol Life Sci; 2016 Feb; 73(3):567-87. PubMed ID: 26514730
[TBL] [Abstract][Full Text] [Related]
56. WNT5A as a therapeutic target in breast cancer.
Prasad CP; Manchanda M; Mohapatra P; Andersson T
Cancer Metastasis Rev; 2018 Dec; 37(4):767-778. PubMed ID: 30171384
[TBL] [Abstract][Full Text] [Related]
57. High levels of WNT-5A in human glioma correlate with increased presence of tumor-associated microglia/monocytes.
Dijksterhuis JP; Arthofer E; Marinescu VD; Nelander S; Uhlén M; Pontén F; Mulder J; Schulte G
Exp Cell Res; 2015 Dec; 339(2):280-8. PubMed ID: 26511503
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer.
Steenbrugge J; Breyne K; Denies S; Dekimpe M; Demeyere K; De Wever O; Vermeulen P; Van Laere S; Sanders NN; Meyer E
J Mammary Gland Biol Neoplasia; 2016 Dec; 21(3-4):113-122. PubMed ID: 27714576
[TBL] [Abstract][Full Text] [Related]
59. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells.
He B; You L; Uematsu K; Xu Z; Lee AY; Matsangou M; McCormick F; Jablons DM
Neoplasia; 2004; 6(1):7-14. PubMed ID: 15068666
[TBL] [Abstract][Full Text] [Related]
60. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.
Kappes L; Amer RL; Sommerlatte S; Bashir G; Plattfaut C; Gieseler F; Gemoll T; Busch H; Altahrawi A; Al-Sbiei A; Haneefa SM; Arafat K; Schimke LF; Khawanky NE; Schulze-Forster K; Heidecke H; Kerstein-Staehle A; Marschner G; Pitann S; Ochs HD; Mueller A; Attoub S; Fernandez-Cabezudo MJ; Riemekasten G; Al-Ramadi BK; Cabral-Marques O
Sci Rep; 2020 Sep; 10(1):15931. PubMed ID: 32985601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
